두개내 동맥류 시장 : 치료법별, 동맥류 부위별, 환자 연령층별, 최종 사용자별 - 세계 예측(2026-2032년)

The Intracranial Aneurysm Market was valued at USD 1.97 billion in 2025 and is projected to grow to USD 2.42 billion in 2026, with a CAGR of 22.95%, reaching USD 8.38 billion by 2032.

A comprehensive introduction framing clinical complexity, diagnostic advances, and multidisciplinary care pathways reshaping intracranial aneurysm management

Intracranial aneurysm management occupies a complex intersection of neurosurgery, endovascular therapy, advanced imaging, and evolving perioperative care models. Over the past decade clinicians and device developers have shifted toward minimally invasive approaches while preserving surgical techniques for anatomically challenging lesions. This convergence has been driven by continuous improvements in device design and imaging resolution, which together improve procedural precision and patient selection.

Contemporary clinical pathways emphasize early detection, risk stratification, and interdisciplinary care planning that integrates neurocritical care, interventional neuroradiology, and neurosurgery. Diagnostic advances such as high-resolution vascular imaging and computational assessments of hemodynamic stress have enhanced clinicians' ability to characterize lesion morphology and rupture risk. Meanwhile, procedural refinements and enhanced perioperative protocols have reduced length of stay and perioperative morbidity, supporting broader adoption of ambulatory and hybrid care models.

Despite technological progress, barriers remain. Anatomical complexity, patient comorbidities, and variability of institutional expertise continue to shape treatment decisions. Reimbursement dynamics, supply chain pressures, and regulatory pathways also influence adoption timelines for novel devices. Consequently, strategic stakeholders must reconcile clinical evidence, operational capacity, and procurement realities to optimize care delivery for patients with intracranial aneurysms.

Rapid advancements in devices, imaging, and procedural strategies are catalyzing a new era of precision care and system-level change for intracranial aneurysm treatment

The landscape of intracranial aneurysm care is experiencing transformative shifts that span device innovation, diagnostic sophistication, and procedural strategy. Device innovation continues to favor low-profile, flexible constructs that accommodate tortuous neurovascular anatomy while improving deliverability and vessel healing. Flow modulation technologies and refinements in coil technology have altered therapeutic algorithms, enabling clinicians to treat anatomies that were once considered high risk for open surgery.

Diagnostics have kept pace through enhanced imaging modalities and the integration of computational tools that quantify aneurysm wall stress and flow patterns. These diagnostic improvements enable more granular risk stratification, guiding the timing and modality of intervention. Procedurally, there is growing adoption of hybrid approaches that combine endovascular and microsurgical techniques when anatomy or prior interventions demand a tailored solution.

Concurrently, systems-level changes-such as the expansion of ambulatory procedural settings and greater emphasis on value-based care-are reshaping where and how treatments are delivered. Partnerships between device manufacturers, clinical centers of excellence, and digital health innovators are accelerating iterative improvements in training, remote proctoring, and outcome monitoring. These cumulative shifts are redefining standard-of-care propositions and creating new opportunities for stakeholders who can align clinical evidence with operational readiness and procurement agility.

Assessment of how the 2025 United States tariff adjustments have reshaped supply chains, procurement practices, and clinical delivery pathways in aneurysm care

The tariff measures implemented in 2025 have introduced a complex overlay of trade policy considerations into the supply chains that support intracranial aneurysm care. Manufacturers that rely on cross-border sourcing for implants, specialized metals, and precision components have faced elevated input costs and extended lead times. In response, many suppliers have reevaluated sourcing footprints, prioritizing supplier diversification and contracts that mitigate single-source dependencies.

Hospital procurement teams and clinical service providers have felt the reverberations through higher acquisition prices for select devices and the need for more rigorous inventory management. These pressures have prompted a shift toward longer-term supplier agreements and increased interest in bundled purchasing arrangements to stabilize unit costs. Regulatory compliance and customs-related administrative burdens have also contributed to slower replenishment cycles, encouraging providers to hold larger safety stocks or to qualify alternative device options to avoid procedural interruptions.

At the strategic level, the tariff environment has accelerated conversations about nearshoring and regional manufacturing partnerships that can reduce exposure to tariff volatility. Device developers and distributors are exploring localized assembly and component sourcing to preserve competitiveness. In parallel, clinicians and hospital leaders are reassessing procurement frameworks to balance cost containment with clinical quality, emphasizing vendor partnerships that demonstrate reliability, local support, and clear post-market surveillance capabilities. These dynamics are reshaping commercial strategies and operational planning across the ecosystem.

Segment-driven insights explaining how treatment modalities, aneurysm locations, patient demographics, and clinical settings influence clinical pathways and adoption dynamics

Segment-level dynamics reveal differentiated adoption patterns and clinical considerations across treatment modalities, anatomical locations, patient demographics, and care settings. When analyzed by treatment type-Endovascular Coiling, Flow Diversion, and Surgical Clipping-each modality presents distinct strengths: coiling remains a mainstay for saccular lesions amenable to endovascular access; flow diversion has expanded options for wide-neck and fusiform aneurysms where vessel reconstruction is desirable; and surgical clipping retains importance for complex bifurcation anatomy and ruptured lesions where immediate mechanical exclusion is required.

Aneurysm location further nuances clinical decision making. Lesions arising in the anterior communicating artery, basilar artery, middle cerebral artery, and posterior communicating artery exhibit unique technical challenges and rupture risk profiles, influencing modality selection, adjunct device use, and anticipated perioperative courses. Patient age group segmentation also affects therapeutic strategy: adult patients commonly present with a wider array of comorbidities that influence antiplatelet planning and device choice, geriatric patients require careful balance between procedural benefit and frailty-related risk, and pediatric cases demand specialized devices and lifelong surveillance strategies that account for growth and long-term durability.

End users shape delivery models and resource allocation. Ambulatory Surgery Centers are increasingly relevant for select elective endovascular cases with predictable recovery trajectories, Diagnostic Centers play a pivotal role in early detection and noninvasive surveillance pathways, and Hospitals continue to be the primary site for complex interventions and acute rupture management due to their integrated critical care and neurosurgical capabilities. Taken together, these segmentation lenses inform clinical pathways, procurement priorities, and investment decisions across the continuum of care.

Regional perspectives on clinical adoption, infrastructure investment, and access pathways shaping intracranial aneurysm care across the Americas, EMEA, and Asia-Pacific

Regional variations in clinical practice, regulatory frameworks, and healthcare infrastructure drive differentiated approaches to intracranial aneurysm care across the major geographies. In the Americas, a concentration of specialized centers, integrated care pathways, and reimbursement models that increasingly reward procedural efficacy support rapid adoption of advanced endovascular techniques and ancillary technologies. Clinical networks and referral patterns in this region often facilitate centralization of high-complexity cases in tertiary centers while enabling ambulatory procedural growth for suitable elective cases.

In Europe, Middle East & Africa, heterogeneity is pronounced: Western European systems frequently combine strong clinical trial ecosystems with well-established neurointerventional programs, whereas segments of the Middle East and Africa are focused on building infrastructure, training local specialists, and improving access to diagnostic imaging. Regulatory harmonization efforts and regional procurement consortia influence device introduction timelines and pricing dynamics, prompting manufacturers to tailor market entry strategies accordingly.

The Asia-Pacific region demonstrates rapid capacity expansion, investment in tertiary neurovascular centers, and a strong emphasis on domestic device development in some countries. A high burden of undiagnosed cerebrovascular disease in certain populations has heightened focus on screening initiatives and diagnostic center expansion. Across all regions, cross-border collaborations, clinical training exchanges, and remote proctoring are increasingly important mechanisms for transferring technique and technology, thereby reducing variability in outcomes and accelerating uptake of evidence-based approaches.

Company-level analysis highlighting how established manufacturers, focused innovators, and service partnerships are reshaping device portfolios and clinical adoption trajectories

Company-level dynamics reflect a blend of entrenched manufacturers, agile specialist firms, and new entrants pushing on innovative device platforms and digital adjuncts. Established medical device companies continue to leverage global distribution channels, regulatory experience, and extensive clinical evidence to support broad clinical adoption of staple technologies. At the same time, specialized firms and startups concentrate on differentiated technical advantages-such as novel flow modulation architectures, bioactive coatings that promote endothelialization, and next-generation delivery systems that prioritize navigability in tortuous anatomy.

Collaborations between device developers and digital health providers are becoming more prevalent, with partnerships focused on advanced imaging analytics, computational fluid modeling, and post-market outcome tracking. These arrangements help demonstrate comparative performance, support clinician training, and generate real-world evidence that can accelerate institutional adoption. In addition, service providers offering end-to-end training, remote proctoring, and device support are gaining prominence as hospitals and ambulatory centers seek to reduce learning curve barriers for complex interventions.

Across the competitive landscape, successful firms combine technical differentiation with robust clinical data, proactive regulatory engagement, and local support capabilities. Companies that invest in clinician education, evidence generation, and supply chain resilience are better positioned to navigate procurement scrutiny and to sustain uptake within high-volume centers as well as emerging treatment sites.

Practical strategic recommendations for device developers, providers, and payers to accelerate innovation adoption, enhance resilience, and improve patient-centered aneurysm care

Industry leaders should prioritize a set of strategic actions to capitalize on clinical innovation while addressing operational and policy constraints. First, aligning product development with clinician-validated use cases and real-world evidence programs will reduce adoption friction and generate compelling value propositions for procurement committees. Close collaboration with high-volume clinical centers for investigator-initiated studies, registries, and training programs can create durable credibility and accelerate dissemination of best practices.

Second, strengthening supply chain resilience is essential. Leaders should diversify sourcing, evaluate regional assembly or nearshoring opportunities, and establish flexible contracting arrangements that include contingency inventory and transparent lead-time commitments. These steps reduce exposure to tariff-driven cost shocks and enhance the ability to support procedural continuity at provider sites.

Third, investing in training and service models that lower procedural learning curves will facilitate broader adoption across hospitals and ambulatory settings. Remote proctoring, modular training curricula, and outcome-driven support models can increase clinician confidence and reduce procedural variability. Fourth, engaging proactively with payers and health systems to articulate cost-effectiveness narratives grounded in clinical outcomes and patient-centered metrics will help align reimbursement pathways with innovation adoption. Finally, leaders should pursue interoperable digital strategies that integrate imaging analytics, outcome registries, and patient-reported outcomes to demonstrate long-term value and support continuous improvement.

Transparent research methodology describing integrated clinical, commercial, and supply chain analyses used to validate insights and support strategic recommendations

The research synthesis draws on a multi-modal methodology that integrates clinical literature review, expert interviews, device labeling and regulatory documentation, and supply chain analyses to assemble a holistic view of intracranial aneurysm care dynamics. Primary qualitative inputs include structured interviews with interventional neuroradiologists, neurosurgeons, procurement leaders, and device design engineers to surface real-world constraints, technology performance considerations, and adoption drivers. These perspectives were triangulated with peer-reviewed clinical studies, procedural guidelines, and public regulatory filings to ensure technical accuracy and clinical relevance.

Supply chain and policy analyses relied on trade data, procurement case studies, and publicly available tariff schedules to assess how recent policy shifts influence device availability and lead times. Where appropriate, the methodology incorporated scenario-based impact assessments to explore potential operational responses to supply disruptions, without producing deterministic forecasts. Data validation steps included cross-referencing expert feedback with documentary evidence, and iterative review cycles to reconcile divergent views and ensure robustness of insights.

The result is a framework that emphasizes clinical, commercial, and operational lenses and that supports actionable recommendations tailored to diverse stakeholders, from device innovators and hospital procurement teams to clinician educators and policy advisors.

Concise conclusion that integrates clinical progress, systemic challenges, and strategic priorities for stakeholders committed to improving aneurysm outcomes and access

This analysis synthesizes clinical innovation, supply chain evolution, and strategic implications to present a cohesive view of current intracranial aneurysm care dynamics. Advances in device technology and imaging have materially expanded therapeutic options, while system-level forces-such as procurement pressures and trade policy shifts-have introduced new operational considerations that affect adoption and access. The intersection of these trends underscores the importance of aligning clinical evidence generation with resilient commercial strategies and targeted clinician support.

Stakeholders who coordinate across clinical, regulatory, and supply chain domains will be best positioned to accelerate durable adoption of beneficial technologies while mitigating disruption. Emphasizing outcomes, investing in clinician training, and pursuing regionally informed supply chain strategies will help institutions maintain procedural continuity and optimize patient outcomes. In sum, the path forward requires integrated planning that balances innovation uptake with pragmatic operational controls, thereby ensuring that clinical advances translate into tangible improvements in patient care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intracranial Aneurysm Market, by Treatment Type

• 8.1. Endovascular Coiling
• 8.2. Flow Diversion
• 8.3. Surgical Clipping

9. Intracranial Aneurysm Market, by Aneurysm Location

• 9.1. Anterior Communicating Artery
• 9.2. Basilar Artery
• 9.3. Middle Cerebral Artery
• 9.4. Posterior Communicating Artery

10. Intracranial Aneurysm Market, by Patient Age Group

• 10.1. Adult
• 10.2. Geriatric
• 10.3. Pediatric

11. Intracranial Aneurysm Market, by End Users

• 11.1. Ambulatory Surgery Centers
• 11.2. Diagnostic Centers
• 11.3. Hospitals

12. Intracranial Aneurysm Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Intracranial Aneurysm Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Intracranial Aneurysm Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Intracranial Aneurysm Market

16. China Intracranial Aneurysm Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Acandis GmbH
• 17.6. B. Braun Melsungen AG
• 17.7. Boston Scientific Corporation
• 17.8. Cook Group Inc
• 17.9. Delta Surgical
• 17.10. Evasc Neurovascular Enterprises ULC
• 17.11. InspireMD Inc
• 17.12. Integer Holdings Corporation
• 17.13. Integra LifeSciences
• 17.14. Johnson & Johnson
• 17.15. Kaneka Corporation
• 17.16. Medtronic plc
• 17.17. Merit Medical Systems Inc
• 17.18. MicroPort Scientific Corporation
• 17.19. Penumbra Inc
• 17.20. Phenox GmbH
• 17.21. Rapid Medical
• 17.22. Raumedic AG
• 17.23. Shape Memory Medical
• 17.24. Stryker Corporation
• 17.25. Terumo Corporation
• 17.26. Wallaby Medical